Overview 2ccPA Study in Patients With Symptomatic Knee Osteoarthritis Status: Completed Trial end date: 2021-03-22 Target enrollment: Participant gender: Summary This clinical trial is designed to determine safety and tolerability as well as the MTD of a single-dose 2ccPA and PK data in symptomatic knee OA. Phase: Phase 1 Details Lead Sponsor: Orient Europharma Co., Ltd.